Early phase drug development company Prophilian has entered this year's coveted Sunday Times Tech Track 100 ranking of the UK's most successful technology companies and organisations
Early phase drug development company Prophilian - which has offices in Nottingham, UK, the United States and Japan - has achieved growth over the past three years of 75% with 2002 sales of £8.97 million.
It was ranked 57th in the national league table and was one of the Midlands' five top performing companies. In its 13-year history, Prophilian has worked with more than 13,000 volunteers in clinical trials.
Principle subsidiaries involved in those trials are Pharmaceutical Profiles, which studies how drugs are absorbed by the body, and Phaeton Research, which examines ways of improving the process.
Together they aim to help pharmaceutical companies save time and money in developing new drugs.
The company is also confident that it can maintain the excellent levels of growth reflected in the Tech Track 100, recently reporting a huge increase in customers committing to its studies.
Much of the work has come from the United States, but there is also plenty of activity from the United Kingdom and Europe.
"Our position in the 100 companies is 57th, which is an excellent achievement and provides recognition of the success and progress the company has made over the years through the provision of innovative technologies and services to our global pharmaceutical client base," stated Ian Wilding, executive chairman of Pharmaceutical Profiles and director of Prophilian.
